PSMA Ligand Linker Optimization for Kidney Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PSMA ligands used in prostate cancer treatment and imaging exhibit high uptake in kidneys, leading to toxicity in patients and suboptimal tumor visualization due to high uptake in other organs.
Innovation Solution
Development of PSMA ligands with a glutamate-urea-lysine (GUL) moiety and a chelating agent, featuring a Cs-alkyl chain linker, which reduces kidney uptake while maintaining high tumor uptake, thereby improving the tumor-to-kidney ratio and minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PSMA ligands with GUL moiety and chelating agent are used for prostate cancer imaging and treatment, then tumor uptake is high, but kidney uptake is also high causing toxicity
Solution Approach 1:
The patent modifies the linker parameters between the GUL moiety and chelating agent, specifically using Cs-alkyl chains with varying lengths (m=1-5) and compositions to optimize the balance between tumor uptake and kidney uptake. By changing the linker parameters, the patent achieves reduced kidney uptake while maintaining high tumor uptake, thereby resolving the toxicity issue.
2Measurement precision
If PSMA ligands are used for imaging, then tumor visualization is needed, but high uptake in other organs reduces visualization quality
Solution Approach 1:
The patent optimizes the linker parameters (Cs-alkyl chain length and composition) to reduce uptake in non-target organs while maintaining high tumor uptake. This parameter optimization improves the tumor-to-kidney ratio and overall image quality by reducing background noise from other organs.
3Object-affected harmful factors
If linker length between GUL and chelating agent is increased, then kidney uptake is reduced, but molecular weight increases
Solution Approach 1:
The patent uses Cs-alkyl linkers with controlled lengths (m=1-5) to achieve the optimal balance between reducing kidney uptake and maintaining acceptable molecular weight. The alkyl chain provides an efficient way to adjust linker length with minimal impact on overall molecular weight compared to other linker types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new PSMA ligands demonstrate a lower uptake in non-target organs, reducing toxicity and enhancing tumor visualization, as evidenced by a higher tumor-to-kidney ratio, facilitating effective imaging and treatment of prostate cancer.
Implementation Method 1
Ch is a chelating agent optionally comprising a metal or a radiometal
Data Source
AI summary
The present disclosure relates to prostate specific membrane antigen (PSMA) ligands. In particular, the disclosure relates to PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal. The disclosure also relates to the use of these compounds in imaging and in the treatment of prostate cancer.